MORRIS PLAINS, N.J., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company was honored by the R&D Council of New Jersey with their coveted Thomas Alva Edison Patent Award, in recognition of the Company’s significant achievements in the medical imaging category for a new method of labeling proteins, peptides and other molecules with fluorine-18 (F-18).
